Last reviewed · How we verify
SVF treatment
At a glance
| Generic name | SVF treatment |
|---|---|
| Sponsor | University of Andorra |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
- Procedural pain
- Arthralgia
- Joint swelling
- Joint stiffness
- Post procedural contusion
- Post procedural haematoma
- Transient pallor in finger after injection
- Transient paresthesia in liposuction lesions
- Dizziness after lidocaine injection
Key clinical trials
- Autologous SVF Therapy for Type 2 Diabetes (NA)
- Stromal Vascular Fraction (SVF) for Knee Post-Trauma Osteoarthritis (PTOA) (EARLY_PHASE1)
- Tolerance of Intra-articular Injection Autologous Stromal Vascular Fraction for the Treatment of Rhizarthrosis (PHASE2)
- Application of Autologous Stem Cells From Adipose Tissue in the Regeneration of Knee Joint Cartilage (PHASE4)
- Intra-articular Transplantation of Autologous Adipose Derived Stromal Vascular Faction (SVF) for Treatment of Osteoarthritis of the Knee (PHASE1)
- Knee Osteoarthritis With Stromal Vascular Fraction Cells (PHASE1, PHASE2)
- PRP vs AD-SVF in Addition to Marrow Stimulation for Knee Chondral Lesion (PHASE4)
- AD-SVF Therapy for Refractory Endometrial Infertility (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SVF treatment CI brief — competitive landscape report
- SVF treatment updates RSS · CI watch RSS
- University of Andorra portfolio CI